bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Table 1-3 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Authors: Beuselinck Benoit , Job Sylvie , Becht Etienne , Karadimou Alexandra , Verkarre Virginie , Couchy Gabrielle , Giraldo Nicolas , Rioux-Leclercq Nathalie , Molinié Vincent , Sibony Mathilde , Elaidi Reza , Teghom Corinne , Patard Jean-Jacques , Méjean Arnaud , Fridman Wolf Herman , Sautès-Fridman Catherine , de Reyniès Aurélien , Oudard Stéphane , Zucman-Rossi Jessica
Published: April 2023

Supplemental Table 1-3. Table S1: Clinical and pathological characteristics of patients. Table S2: List of the 70 genes used for quantitative Real-Time PCR, their Applied Biosystems Assay ID number and the subgroups in which the genes are up- or down-regulated in the Affymetrix data. Table S3: (A) Diagram showing the different analyses that have been done on the samples and (B) sample list according to the different technologies.
Supplementary Figure 2 from Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Authors: Ziemke Elizabeth K. , Dosch Joseph S. , Maust Joel D. , Shettigar Amrith , Sen Ananda , Welling Theodore H. , Hardiman Karin M. , Sebolt-Leopold Judith S.
Published: April 2023

pRB Expression in Individual Colorectal Cancer PDX Models. Immunoblotting analysis of pRB expression (ser780) in 18 different CRC PDX models.
Supplementary Figure 1 from Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Authors: Ziemke Elizabeth K. , Dosch Joseph S. , Maust Joel D. , Shettigar Amrith , Sen Ananda , Welling Theodore H. , Hardiman Karin M. , Sebolt-Leopold Judith S.
Published: April 2023

Body Weight Change in Mice Treated with Trametinib and/or Palbociclib. Toxicity assessment of single agent and combination therapy with trametinib and palbociclib.
Supplemental Figure 4-6 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Authors: Beuselinck Benoit , Job Sylvie , Becht Etienne , Karadimou Alexandra , Verkarre Virginie , Couchy Gabrielle , Giraldo Nicolas , Rioux-Leclercq Nathalie , Molinié Vincent , Sibony Mathilde , Elaidi Reza , Teghom Corinne , Patard Jean-Jacques , Méjean Arnaud , Fridman Wolf Herman , Sautès-Fridman Catherine , de Reyniès Aurélien , Oudard Stéphane , Zucman-Rossi Jessica
Published: April 2023

Supplemental Figure 4-6. Figure S4: Characterisation of the ccRCC molecular subtypes: methylation status and Benporath polycomb signature; Figure S5: Cytogenetic characterization of the ccRCC molecular subtypes; Figure S6: Characterization of the ccRCC molecular subtypes: Myc methylation and (target) amplification
rhIL-1RA increase Gemcitabine chemosensitivity by inhibiting NF-κB Activation from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Authors: Zhuang Zhuonan , Ju Huai-Qiang , Aguilar Mitzi , Gocho Takashi , Li Hao , Iida Tomonori , Lee Harold , Fan Xiaoqiang , Zhou Haijun , Ling Jianhua , Li Zhongkui , Fu Jie , Wu Min , Li Min , Melisi Davide , Iwakura Yoichiro , Xu Kesen , Fleming Jason B. , Chiao Paul J.
Published: April 2023

We found that rhIL-1RA inhibits IL-1 receptor activation and NF-κB activity. Furthermore, in PDAC cells treated with or without gemcitabine, rhIL-1RA significantly decreases proliferation, migration, invasion, and tumor burden in orthotopic nude mouse model (gemcitabine plus rhIL-1RA vs. control, P=0.014). Thus, these results suggest that IL-1RA can reduce tumor growth by inhibiting IL-1a -induced NF-kB activity; the result also suggests that IL-R is a potential surrogate therapeutic target for mutant Kras and activated NF-kB in treatment of PDAC.
Supplementary Data (for publication) from Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression
Authors: Evageliou Nicholas F. , Haber Michelle , Vu Annette , Laetsch Theodore W. , Murray Jayne , Gamble Laura D. , Cheng Ngan Ching , Liu Kangning , Reese Megan , Corrigan Kelly A. , Ziegler David S. , Webber Hannah , Hayes Candice S. , Pawel Bruce , Marshall Glenn M. , Zhao Huaqing , Gilmour Susan K. , Norris Murray D. , Hogarty Michael D.
Published: April 2023

Supplementary Methods, Tables and Figures
Supplemental Table S1, Table S2 and Table S3 from Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Authors: Hoffman-Luca C. Gianna , Ziazadeh Daniel , McEachern Donna , Zhao Yujun , Sun Wei , Debussche Laurent , Wang Shaomeng
Published: April 2023

Supplemental Table S1, Table S2 and Table S3. Table S1. Sequencing of p53 in RS4;11 cell lines. Table S2. Combination index analysis of and SAR405838 and ABT-263 in the RS4;11 and MV4;11 cell lines in cell growth assay. Table S3. Combination index analysis of and SAR405838 and ABT-263 in the RS4;11 and MV4;11 cell lines in apoptosis assay.
Figure S3 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Authors: Zhuang Zhuonan , Ju Huai-Qiang , Aguilar Mitzi , Gocho Takashi , Li Hao , Iida Tomonori , Lee Harold , Fan Xiaoqiang , Zhou Haijun , Ling Jianhua , Li Zhongkui , Fu Jie , Wu Min , Li Min , Melisi Davide , Iwakura Yoichiro , Xu Kesen , Fleming Jason B. , Chiao Paul J.
Published: April 2023

Figure S3. A, B, Cell growth was assessed by the MTT and colony formation assays.
Figure S2 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Authors: Zhuang Zhuonan , Ju Huai-Qiang , Aguilar Mitzi , Gocho Takashi , Li Hao , Iida Tomonori , Lee Harold , Fan Xiaoqiang , Zhou Haijun , Ling Jianhua , Li Zhongkui , Fu Jie , Wu Min , Li Min , Melisi Davide , Iwakura Yoichiro , Xu Kesen , Fleming Jason B. , Chiao Paul J.
Published: April 2023

Figure S2. A, Western blot analysis to determine the phosphorylation of P65 in AsPc1 cells pretreated with 50 μM NAC (a ROS scavenger) for 1 hour followed by treatment with gemcitabine (Gem, 10μM).
Supplemental Figure S7 and Figure S8 from Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Authors: Hoffman-Luca C. Gianna , Ziazadeh Daniel , McEachern Donna , Zhao Yujun , Sun Wei , Debussche Laurent , Wang Shaomeng
Published: April 2023

Supplemental Figure S7 and Figure S8. Characterization of sublines established from in vivo treatment of the MV4;11 xenograft tumors in mice with SAR or ABT-263 for their response to SAR (Figure S7) or to ABT-263 (Figure S8).
Supplementary Table 3 from MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis
Authors: Tong Joanna H. , Yeung Sai F. , Chan Anthony W.H. , Chung Lau Y. , Chau Shuk L. , Lung Raymond Wai Ming , Tong Carol Y. , Chow Chit , Tin Edith K.Y. , Yu Yau H. , Li Hui , Pan Yi , Chak Wing P. , Ng Calvin S.H. , Mok Tony S.K. , To Ka F.
Published: April 2023

Clinicopathologic features of NSCLC patients according to MET FISH status by different scoring systems
Supplemental Figure S1 and Figure S2. from Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Authors: Hoffman-Luca C. Gianna , Ziazadeh Daniel , McEachern Donna , Zhao Yujun , Sun Wei , Debussche Laurent , Wang Shaomeng
Published: April 2023

Supplemental Figure S1 and Figure S2. Figure S1. Further characterization of RS4;11 sublines established from in vivo treatment of RS4;11 xenograft tumors in mice with ABT-737. Figure S2. Further characterization of RS4;11 sublines established from in vivo treatment of RS4;11 xenograft tumors in mice with SAR405838.
Supplementary Tables S1-5 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Authors: O'Shaughnessy Joyce , Koeppen Hartmut , Xiao Yuanyuan , Lackner Mark R. , Paul Devchand , Stokoe Christopher , Pippen John , Krekow Lea , Holmes Frankie Ann , Vukelja Svetislava , Lindquist Deborah , Sedlacek Scot , Rivera Ragene , Brooks Robert , McIntyre Kristi , Brownstein Carrie , Hoersch Silke , Blum Joanne L. , Jones Stephen
Published: April 2023

Supplementary Tables S1-5. Table S1. Baseline demographic and disease characteristics of patients with central Ki-67 data available. Table S2. Concordance between central and local Ki-67 scores. Table S3. Percentage of patients with a DFS event or death in lobular versus ductal early breast cancer (exploratory analysis). Table S4. 7-year DFS and OS by central Ki-67 scores (exploratory analysis). Table S5. 5-year DFS and OS by local Ki-67 scores (exploratory analysis).
Supplementary Figure 1 from MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis
Authors: Tong Joanna H. , Yeung Sai F. , Chan Anthony W.H. , Chung Lau Y. , Chau Shuk L. , Lung Raymond Wai Ming , Tong Carol Y. , Chow Chit , Tin Edith K.Y. , Yu Yau H. , Li Hui , Pan Yi , Chak Wing P. , Ng Calvin S.H. , Mok Tony S.K. , To Ka F.
Published: April 2023

Venn Diagrams illustrating the computation of four categories of MET CNA and their association with MET protein expression
Supplementary Figure 3 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Authors: O'Shaughnessy Joyce , Koeppen Hartmut , Xiao Yuanyuan , Lackner Mark R. , Paul Devchand , Stokoe Christopher , Pippen John , Krekow Lea , Holmes Frankie Ann , Vukelja Svetislava , Lindquist Deborah , Sedlacek Scot , Rivera Ragene , Brooks Robert , McIntyre Kristi , Brownstein Carrie , Hoersch Silke , Blum Joanne L. , Jones Stephen
Published: April 2023

Figure S3: Forest plots for DFS comparing patients with central Ki-67 high versus low based on quartile cutoffs (exploratory analysis) in (A) ER-positive/HER2-negative breast cancer (n=824) and (B) TNBC (n=454)
Supplementary tables S1-8 from Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer
Authors: Yuan Hua , Chen Jiuan , Liu Yiqiang , Ouyang Tao , Li Jinfeng , Wang Tianfeng , Fan Zhaoqing , Fan Tie , Lin Benyao , Xie Yuntao
Published: April 2023

Supplementary tables S1-8. Supplementary Table S1. Primers Used for PCR Amplification of PIK3CA Entire Coding Regions Supplementary Table S2. Frequency of PIK3CA Mutations in Different Subgroups Supplementary Table S3. Multivariate Analyses of Pathological Complete Response in the Entire Study Population (n=729) Supplementary Table S4. Pathological Complete Response Rates in Patients with PIK3CA Hotspot and Non-hotspot Mutations Supplementary Table S5. Pathological Complete Response Rates in Patients with Different PIK3CA Hotspot Mutations Supplementary Table S6. Pathological Complete Response Rates by PIK3CA Status in Different Subgroups Supplementary Table S7. Breast cancer subgroups in the 102 Patients whose PIK3CA Mutation Status was Available before and after Neoadjuvant Chemotherapy Supplementary Table S8. Multivariate Analyses of DFS and DDFS in the 102 Patients whose PIK3CA Mutation Status was Available before and after Neoadjuvant Chemotherapy
Supplementary Figures S1-6 from Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer
Authors: Yuan Hua , Chen Jiuan , Liu Yiqiang , Ouyang Tao , Li Jinfeng , Wang Tianfeng , Fan Zhaoqing , Fan Tie , Lin Benyao , Xie Yuntao
Published: April 2023

Supplementary Figures S1-6. Supplementary Fig. S1. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA mutations in different hotspots. Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S2. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in the entire study population (n=729). Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S3. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in the luminal subgroup (n=376). Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S4. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in the HER2-positive patients who did not receive trastuzumab treatment (n=181). Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S5. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in the HER2-positive patients who received trastuzumab treatment (n=41). Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S6. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in TN subgroup (n=128). Disease-free survival (Panel A); Distant disease-free survival (Panel B).
Supplementary Figure 6 from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Liu Hongyan , Ai Jing , Shen Aijun , Chen Yi , Wang Xinyi , Peng Xia , Chen Hui , Shen Yanyan , Huang Min , Ding Jian , Geng Meiyu
Published: April 2023

c-Myc indicates the therapeutic response to FGFR inhibition in vivo. A
Supplementary Figure 5 from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Liu Hongyan , Ai Jing , Shen Aijun , Chen Yi , Wang Xinyi , Peng Xia , Chen Hui , Shen Yanyan , Huang Min , Ding Jian , Geng Meiyu
Published: April 2023

FGFR inhibition facilitates c-Myc protein degradation in FGFR-addicted cancer cells.
Supplemental Figure 2 from Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
Authors: Ory Benjamin , Baud'huin Marc , Verrecchia Franck , Royer Bénédicte Brounais-Le , Quillard Thibaut , Amiaud Jérôme , Battaglia Séverine , Heymann Dominique , Redini Francoise , Lamoureux Francois
Published: April 2023

Supp. Figure 2. HSP90 inhibition induces client proteins degradation.
supplemental figure legend from Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Authors: Bellini Angela , Bernard Virginie , Leroy Quentin , Rio Frio Thomas , Pierron Gaelle , Combaret Valérie , Lapouble Eve , Clement Nathalie , Rubie Herve , Thebaud Estelle , Chastagner Pascal , Defachelles Anne Sophie , Bergeron Christophe , Buchbinder Nimrod , Taque Sophie , Auvrignon Anne , Valteau-Couanet Dominique , Michon Jean , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun
Published: April 2023

supplemental figure legend. supplemental figure legend
CCR-15-2448-Supplementary from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Liu Hongyan , Ai Jing , Shen Aijun , Chen Yi , Wang Xinyi , Peng Xia , Chen Hui , Shen Yanyan , Huang Min , Ding Jian , Geng Meiyu
Published: April 2023

CCR-15-2448-Supplementary-revision
Supplementary Figure 1 from Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Authors: Bellini Angela , Bernard Virginie , Leroy Quentin , Rio Frio Thomas , Pierron Gaelle , Combaret Valérie , Lapouble Eve , Clement Nathalie , Rubie Herve , Thebaud Estelle , Chastagner Pascal , Defachelles Anne Sophie , Bergeron Christophe , Buchbinder Nimrod , Taque Sophie , Auvrignon Anne , Valteau-Couanet Dominique , Michon Jean , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun
Published: April 2023

Supplementary Figure 1. Background variability observed by high coverage Hiseq2500 Illumina® sequencing in 24 germline DNA controls.
Supplementary materials from The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Authors: Zhao Shuang G. , Evans Joseph R. , Kothari Vishal , Sun Grace , Larm Ashley , Mondine Victor , Schaeffer Edward M. , Ross Ashley E. , Klein Eric A. , Den Robert B. , Dicker Adam P. , Karnes R. Jeffrey , Erho Nicholas , Nguyen Paul L. , Davicioni Elai , Feng Felix Y.
Published: April 2023

Supplementary figure legends and tables.
Supplemental Figure 4. from The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Authors: Zhao Shuang G. , Evans Joseph R. , Kothari Vishal , Sun Grace , Larm Ashley , Mondine Victor , Schaeffer Edward M. , Ross Ashley E. , Klein Eric A. , Den Robert B. , Dicker Adam P. , Karnes R. Jeffrey , Erho Nicholas , Nguyen Paul L. , Davicioni Elai , Feng Felix Y.
Published: April 2023

Supplemental Figure 4. Prognostic outlier score and overall survival.
Supplementary Tables 1 - 3 from Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic
Authors: Jardim Denis L.F. , Tang Chad , Gagliato Debora De Melo , Falchook Gerald S. , Hess Kenneth , Janku Filip , Fu Siqing , Wheler Jennifer J. , Zinner Ralph G. , Naing Aung , Tsimberidou Apostolia M. , Holla Vijaykumar , Li Marylin M. , Roy-Chowdhuri Sinchita , Luthra Raja , Salgia Ravi , Kurzrock Razelle , Meric-Bernstam Funda , Hong David S.
Published: April 2023

Table S1 - Histologies and tumor grade by site according to MET amplification status. Table S2- Type of BRAF mutations by tumor site. Table S3 - List of phase I trials included as best trials for MET amplified patients.
Supplemental Figure 3. from The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Authors: Zhao Shuang G. , Evans Joseph R. , Kothari Vishal , Sun Grace , Larm Ashley , Mondine Victor , Schaeffer Edward M. , Ross Ashley E. , Klein Eric A. , Den Robert B. , Dicker Adam P. , Karnes R. Jeffrey , Erho Nicholas , Nguyen Paul L. , Davicioni Elai , Feng Felix Y.
Published: April 2023

Supplemental Figure 3. Metastatic progression association in discovrey cohort.
Supplemental Figure 2. from The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Authors: Zhao Shuang G. , Evans Joseph R. , Kothari Vishal , Sun Grace , Larm Ashley , Mondine Victor , Schaeffer Edward M. , Ross Ashley E. , Klein Eric A. , Den Robert B. , Dicker Adam P. , Karnes R. Jeffrey , Erho Nicholas , Nguyen Paul L. , Davicioni Elai , Feng Felix Y.
Published: April 2023

Supplemental Figure 2. Additional prognostic outlier negative result examples.
supplemental material-Figure S6 from Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
Authors: Guo Xingjun , Zheng Lei , Jiang Jianxin , Zhao Yan , Wang Xin , Shen Ming , Zhu Feng , Tian Rui , Shi Chengjian , Xu Meng , Li Xu , Peng Feng , Zhang Hang , Feng Yechen , Xie Yu , Xu Xiaodong , Jia Wei , He Ruizhi , Xie Chencheng , Hu Jun , Ye Dawei , Wang Min , Qin Renyi
Published: April 2023

Figure S6: IL-18 promotes proliferation and invasion of PC cells via the NF-κB pathway.
Supplementary Table 1 from Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy
Authors: Schouten Philip C. , Marmé Frederik , Aulmann Sebastian , Sinn Hans-Peter , van Essen Hendrik F. , Ylstra Bauke , Hauptmann Michael , Schneeweiss Andreas , Linn Sabine C.
Published: April 2023

Supplementary Table 1. Description of the study according to REMARK.
supplemental material-Figure S5 from Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
Authors: Guo Xingjun , Zheng Lei , Jiang Jianxin , Zhao Yan , Wang Xin , Shen Ming , Zhu Feng , Tian Rui , Shi Chengjian , Xu Meng , Li Xu , Peng Feng , Zhang Hang , Feng Yechen , Xie Yu , Xu Xiaodong , Jia Wei , He Ruizhi , Xie Chencheng , Hu Jun , Ye Dawei , Wang Min , Qin Renyi
Published: April 2023

Figure S5: IL-18 promotes PC cell proliferation, invasion and metastasis.
Supplementary Figures 1-4 from Nuclear Trapping through Inhibition of Exosomal Export by Indomethacin Increases Cytostatic Efficacy of Doxorubicin and Pixantrone
Authors: Koch Raphael , Aung Thiha , Vogel Daniel , Chapuy Bjoern , Wenzel Dirk , Becker Sabrina , Sinzig Ursula , Venkataramani Vivek , von Mach Tobias , Jacob Ralf , Truemper Lorenz , Wulf Gerald G.
Published: April 2023

Supp. Figure 1 (Detection of doxorubicin in the exosomes by HPLC and visualization of vesicular Transport); Supp. Figure 2 (DLBCL in ovo xenotransplantation model); Supp. Figure 3 (Increased cytotoxicity pixantrone and doxorubicin against DLBCL-ABC cell line OCI-Ly3 by pretreatment with indomethacin); Supp. Figure 4 (Celecoxib and omeprazole do not alter doxorubicin-susceptibility in SU-DHL-4 and OCI-Ly1 cells).
supplemental material-Figure S2 from Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
Authors: Guo Xingjun , Zheng Lei , Jiang Jianxin , Zhao Yan , Wang Xin , Shen Ming , Zhu Feng , Tian Rui , Shi Chengjian , Xu Meng , Li Xu , Peng Feng , Zhang Hang , Feng Yechen , Xie Yu , Xu Xiaodong , Jia Wei , He Ruizhi , Xie Chencheng , Hu Jun , Ye Dawei , Wang Min , Qin Renyi
Published: April 2023

Figure S2: IL-18 receptor (IL-18R) expression in pancreatic cancer tissues and cell lines.
Supplementary Figure Legend from Nuclear Trapping through Inhibition of Exosomal Export by Indomethacin Increases Cytostatic Efficacy of Doxorubicin and Pixantrone
Authors: Koch Raphael , Aung Thiha , Vogel Daniel , Chapuy Bjoern , Wenzel Dirk , Becker Sabrina , Sinzig Ursula , Venkataramani Vivek , von Mach Tobias , Jacob Ralf , Truemper Lorenz , Wulf Gerald G.
Published: April 2023

Supplementary figure legend
supplemental material-Figure S1 from Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
Authors: Guo Xingjun , Zheng Lei , Jiang Jianxin , Zhao Yan , Wang Xin , Shen Ming , Zhu Feng , Tian Rui , Shi Chengjian , Xu Meng , Li Xu , Peng Feng , Zhang Hang , Feng Yechen , Xie Yu , Xu Xiaodong , Jia Wei , He Ruizhi , Xie Chencheng , Hu Jun , Ye Dawei , Wang Min , Qin Renyi
Published: April 2023

Figure S1: IL-18 is higher in PC tissues and correlates with poorer survival. Immunohistochemical (IHC) staining of IL-18
Supplementary Tables 1,2,3,4 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Authors: Vitale Candida , Falchi Lorenzo , ten Hacken Elisa , Gao Hui , Shaim Hila , Van Roosbroeck Katrien , Calin George , O'Brien Susan , Faderl Stefan , Wang Xuemei , Wierda William G. , Rezvani Katayoun , Reuben James M. , Burger Jan A. , Keating Michael J. , Ferrajoli Alessandra
Published: April 2023

Supplementary Table 1: Inclusion and exclusion criteria. Supplementary Table 2: Lenalidomide dose reduction steps. Supplementary Table 3: Overall and complete response rates according to pre-treatment characteristics. Supplementary Table 4: Causes of death.
Supplemental Material and Methods from Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
Authors: Guo Xingjun , Zheng Lei , Jiang Jianxin , Zhao Yan , Wang Xin , Shen Ming , Zhu Feng , Tian Rui , Shi Chengjian , Xu Meng , Li Xu , Peng Feng , Zhang Hang , Feng Yechen , Xie Yu , Xu Xiaodong , Jia Wei , He Ruizhi , Xie Chencheng , Hu Jun , Ye Dawei , Wang Min , Qin Renyi
Published: April 2023

Supplemental Material and Methods
Supplementary Figure S6 from Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness
Authors: Li Zhiwei , Jia Zhiliang , Gao Yong , Xie Dacheng , Wei Daoyan , Cui Jiujie , Mishra Lopa , Huang Suyun , Zhang Yanqiao , Xie Keping
Published: April 2023

Supplementary Figure S6. Impact of altered VDR signaling on FOXM1 expression and pancreatic tumor growth in vivo
Supplementary Figure S2 from Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness
Authors: Li Zhiwei , Jia Zhiliang , Gao Yong , Xie Dacheng , Wei Daoyan , Cui Jiujie , Mishra Lopa , Huang Suyun , Zhang Yanqiao , Xie Keping
Published: April 2023

Supplementary Figure S2. Vitamin D treatment preferentially reduced the expression of ÃŽÂ²-catenin and E-cadherin in the nuclear compartment
Supplementary Figure S1 from Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness
Authors: Li Zhiwei , Jia Zhiliang , Gao Yong , Xie Dacheng , Wei Daoyan , Cui Jiujie , Mishra Lopa , Huang Suyun , Zhang Yanqiao , Xie Keping
Published: April 2023

Supplementary Figure S1. Additional evidences support that VDR signaling regulates FOXM1 expression in human PDAC cells
Supplementary table 2 from Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Authors: Yaeger Rona , Cercek Andrea , O'Reilly Eileen M. , Reidy Diane L. , Kemeny Nancy , Wolinsky Tamar , Capanu Marinela , Gollub Marc J. , Rosen Neal , Berger Michael F. , Lacouture Mario E. , Vakiani Efsevia , Saltz Leonard B.
Published: April 2023

Supplementary table 2. Tumor genetic mutations identified with next generation sequencing
Supplementary table 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Authors: van Gool Inge C. , Eggink Florine A. , Freeman-Mills Luke , Stelloo Ellen , Marchi Emanuele , de Bruyn Marco , Palles Claire , Nout Remi A. , de Kroon Cor D. , Osse Elisabeth M. , Klenerman Paul , Creutzberg Carien L. , Tomlinson Ian P.M. , Smit Vincent T.H.B.M. , Nijman Hans W. , Bosse Tjalling , Church David N.
Published: April 2023

Supplementary table 1. Demographic and clinicopathological characteristics of cases by EC molecular subtype
Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
Authors: Poulain Stéphanie , Roumier Christophe , Venet-Caillault Aurélie , Figeac Martin , Herbaux Charles , Marot Guillemette , Doye Emmanuelle , Bertrand Elisabeth , Geffroy Sandrine , Lepretre Frédéric , Nibourel Olivier , Decambron Audrey , Boyle Eileen Mary , Renneville Aline , Tricot Sabine , Daudignon Agnès , Quesnel Bruno , Duthilleul Patrick , Preudhomme Claude , Leleu Xavier
Published: April 2023

Characteristics of patients with WM
Supplementary Figure S5 from Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
Authors: Amaral Ana Teresa , Garofalo Cecilia , Frapolli Roberta , Manara Maria Cristina , Mancarella Caterina , Uboldi Sarah , Giandomenico Silvana Di , Ordóñez Jose Luis , Sevillano Victoria , Malaguarnera Roberta , Picci Piero , Hassan A. Bass , Alava Enrique De , D'Incalci Maurizio , Scotlandi Katia
Published: April 2023

Supplementary Figure S5. DNA damage repair pathways after treatment of TC-71 cells with trabectedin or OSI-906
Supplemental Table 1 Gene expression profilling from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
Authors: Poulain Stéphanie , Roumier Christophe , Venet-Caillault Aurélie , Figeac Martin , Herbaux Charles , Marot Guillemette , Doye Emmanuelle , Bertrand Elisabeth , Geffroy Sandrine , Lepretre Frédéric , Nibourel Olivier , Decambron Audrey , Boyle Eileen Mary , Renneville Aline , Tricot Sabine , Daudignon Agnès , Quesnel Bruno , Duthilleul Patrick , Preudhomme Claude , Leleu Xavier
Published: April 2023

Gene expression profilling : List of deregulated gene identified by gene expression profilling using U133 Plus 2.0 arrays (Affymetrix, USA)
Supplementary Figure S3 from Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
Authors: Amaral Ana Teresa , Garofalo Cecilia , Frapolli Roberta , Manara Maria Cristina , Mancarella Caterina , Uboldi Sarah , Giandomenico Silvana Di , Ordóñez Jose Luis , Sevillano Victoria , Malaguarnera Roberta , Picci Piero , Hassan A. Bass , Alava Enrique De , D'Incalci Maurizio , Scotlandi Katia
Published: April 2023

Supplementary Figure S3. Modulation of IGF-1R expression after transient silencing of EWS-FLI1 in EWS.
Supplemental Figures 1 - 6, Table 1 from Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer
Authors: Knowles Scott M. , Tavaré Richard , Zettlitz Kirstin A. , Rochefort Matthew M. , Salazar Felix B. , Jiang Ziyue Karen , Reiter Robert E. , Wu Anna M.
Published: April 2023

Supplemental Figure 1: Transfection of 22rv1 with FLuc-IRES-mCherry and 22rv1_PSCA with Fluc-IRES-GFP and FACS sorting created FLuc expressing PSCA positive and negative cell lines. Supplemental Figure 2: H&E Staining of 22rv1 and 22rv1_PSCA intratibial xenografts shows mixed osteolytic (blue dashed arrows) and osteoblastic (solid red arrows) type tumor formation. Supplemental Figure 3: Comparison of optical imaging, 18F-Fluoride Bone Scan, and A11 immunoPET in mice bearing 22rv1 intratibial xenograft 6 weeks post-xenograftimplantation. Supplemental Figure 4: Comparison of optical imaging, 18F-Fluoride Bone Scan, and A11 immunoPET in a mouse bearing a 22rv1_PSCA intratibial xenograft at 2 and 6 weeks postxenograft- implantation. Supplemental Figure 5: Quantification of tumor necrosis using ImageJ based color Segmentation. Supplemental Figure 6: H&E staining of LAPC-9 tumors treated with either MDV-3100 or vehicle control. Supplemental Table 1: 44 hour biodistribution of mice bearing 22rv1 and 22rv1_PSCA intratibial xenografts. Histologic analysis of control and MDV-3100 treated tumors.
Supplementary Table 2 from Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients
Authors: Mayerhoefer Marius E. , Karanikas Georgios , Kletter Kurt , Prosch Helmut , Kiesewetter Barbara , Skrabs Cathrin , Porpaczy Edit , Weber Michael , Knogler Thomas , Sillaber Christian , Jaeger Ulrich , Simonitsch-Klupp Ingrid , Ubl Philipp , Müllauer Leonhard , Dolak Werner , Lukas Julius , Raderer Markus
Published: April 2023

Supplementary Table 2. True positive (TP), false negative (FN), false positive (FP), and true negative (TN) regions for DWI-MRI at follow-up, relative to 18F-FDG-PET/CT
Supplementary Table S6 from LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
Authors: Torres Sofía , Garcia-Palmero Irene , Herrera Mercedes , Bartolomé Rubén A. , Peña Cristina , Fernandez-Aceñero M. Jesús , Padilla Guillermo , Peláez-García Alberto , Lopez-Lucendo María , Rodriguez-Merlo Rufo , de Herreros Antonio García , Bonilla Félix , Casal J. Ignacio
Published: April 2023

Supplementary Table S6. Relationship between clinicopathologic parameters and LOXL2 expression in patients with colorectal carcinoma
Supplementary Table S2 from LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
Authors: Torres Sofía , Garcia-Palmero Irene , Herrera Mercedes , Bartolomé Rubén A. , Peña Cristina , Fernandez-Aceñero M. Jesús , Padilla Guillermo , Peláez-García Alberto , Lopez-Lucendo María , Rodriguez-Merlo Rufo , de Herreros Antonio García , Bonilla Félix , Casal J. Ignacio
Published: April 2023

Supplementary Table S2. Global list of proteins identified and quantified in the whole cellular extract and conditioned medium of CAFs
Supplementary Methods from LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
Authors: Torres Sofía , Garcia-Palmero Irene , Herrera Mercedes , Bartolomé Rubén A. , Peña Cristina , Fernandez-Aceñero M. Jesús , Padilla Guillermo , Peláez-García Alberto , Lopez-Lucendo María , Rodriguez-Merlo Rufo , de Herreros Antonio García , Bonilla Félix , Casal J. Ignacio
Published: April 2023

Supplementary Methodology
Supplementary Table S5. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Authors: Jenkinson Claire , Elliott Victoria L. , Evans Anthony , Oldfield Lucy , Jenkins Rosalind E. , O'Brien Darragh P. , Apostolidou Sophia , Gentry-Maharaj Aleksandra , Fourkala Evangelia-O , Jacobs Ian J. , Menon Usha , Cox Trevor , Campbell Fiona , Pereira Stephen P. , Tuveson David A. , Park B. Kevin , Greenhalf William , Sutton Robert , Timms John F. , Neoptolemos John P. , Costello Eithne
Published: April 2023

Comparison of TSP-1 tissue expression in PDAC patients with clinicopathological parameters.
Supplementary Figure S1 from Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Authors: Janni Wolfgang J. , Rack Brigitte , Terstappen Leon W.M.M. , Pierga Jean-Yves , Taran Florin-Andrei , Fehm Tanja , Hall Carolyn , de Groot Marco R. , Bidard François-Clement , Friedl Thomas W.P. , Fasching Peter A. , Brucker Sara Y. , Pantel Klaus , Lucci Anthony
Published: April 2023

Figure S1. Flow chart of the data selection process for a pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer. Patients were ineligible if no valid data on CTC presence at the time of primary diagnosis as assessed using the FDA-cleared CellSearch® System were available (e.g., because of insufficient amount of blood or test failure). * A total of 3,754 patients with early breast cancer were randomized in the SUCCESS A clinical trial; however, blood samples for the enumeration of CTCs with the CellSearch® System were only collected after written informed consent from 1,994 of those patients.
Supplementary Material S1 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma
Authors: Ekmekcioglu Suhendan , Davies Michael A. , Tanese Keiji , Roszik Jason , Shin-Sim Myung , Bassett Roland L. , Milton Denái R. , Woodman Scott E. , Prieto Victor G. , Gershenwald Jeffrey E. , Morton Donald L. , Hoon Dave S. , Grimm Elizabeth A.
Published: April 2023

This text includes the primary antibodies which were previously tested and validated by us for IHC using tumor and controls.
Supplementary Table 6 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Authors: Adjei Alex A. , Richards Donald A. , El-Khoueiry Anthony , Braiteh Fadi , Becerra Carlos H.R. , Stephenson Joe J. , Hezel Aram F. , Sherman Morris , Garbo Lawrence , Leffingwell Diane P. , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Gunawan Sonny , Wilson David M. , Manhard Kimberly J. , Rajagopalan Prabhu , Krissel Heiko , Clendeninn Neil J.
Published: April 2023

Sorafenib geometric mean (% coefficient of variation) multiple-dose pharmacokinetic data on day 1 of course 2
Supplementary Table 5 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Authors: Adjei Alex A. , Richards Donald A. , El-Khoueiry Anthony , Braiteh Fadi , Becerra Carlos H.R. , Stephenson Joe J. , Hezel Aram F. , Sherman Morris , Garbo Lawrence , Leffingwell Diane P. , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Gunawan Sonny , Wilson David M. , Manhard Kimberly J. , Rajagopalan Prabhu , Krissel Heiko , Clendeninn Neil J.
Published: April 2023

Refametinib geometric mean (% coefficient of variation) multiple-dose pharmacokinetic data on day 1 of course 2
Supplementary Table 2 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Authors: Adjei Alex A. , Richards Donald A. , El-Khoueiry Anthony , Braiteh Fadi , Becerra Carlos H.R. , Stephenson Joe J. , Hezel Aram F. , Sherman Morris , Garbo Lawrence , Leffingwell Diane P. , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Gunawan Sonny , Wilson David M. , Manhard Kimberly J. , Rajagopalan Prabhu , Krissel Heiko , Clendeninn Neil J.
Published: April 2023

Grade 3 or 4 adverse events possibly related to refametinib or sorafenib, occurring in {greater than or equal to}2 patients in either cohort
Supplementary figures S1-S5 from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
Authors: Niemann Carsten U. , Herman Sarah E.M. , Maric Irina , Gomez-Rodriguez Julio , Biancotto Angelique , Chang Betty Y. , Martyr Sabrina , Stetler-Stevenson Maryalice , Yuan Constance M. , Calvo Katherine R. , Braylan Raul C. , Valdez Janet , Lee Yuh Shan , Wong Deanna H. , Jones Jade , Sun Clare , Marti Gerald E. , Farooqui Mohammed Z.H. , Wiestner Adrian
Published: April 2023

Supplementary Figure S1. Ibrutinib alters the absolute expression of inflammatory cytokines and chemokines in serum from patients with CLL. Supplementary Figure S2. Ibrutinib treatment reduces tumor burden. Supplementary Figure S3. Both CD4+ and CD8+ T cell subsets are decreased on ibrutinib. Supplementary Figure S4. Grading of macrophage interaction with CLL cells in bone marrow specimens. Supplementary Figure S5. Ibrutinib alters the absolute expression of chemokines in bone marrow supernatant from patients with CLL.
Supplementary Video A from Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Authors: Krishnamurthy Janani , Rabinovich Brian A. , Mi Tiejuan , Switzer Kirsten C. , Olivares Simon , Maiti Sourindra N. , Plummer Joshua B. , Singh Harjeet , Kumaresan Pappanaicken R. , Huls Helen M. , Wang-Johanning Feng , Cooper Laurence J.N.
Published: April 2023

Supplementary Video A. VTLM single cell killing of A888 tumor cells by HERV-K env-specific CAR+ T cells
Supplementary Figure 3 from Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
Authors: Chau Nicole G. , Li Yvonne Y. , Jo Vickie Y. , Rabinowits Guilherme , Lorch Jochen H. , Tishler Roy B. , Margalit Danielle N. , Schoenfeld Jonathan D. , Annino Don J. , Goguen Laura A. , Thomas Tom , Becker Hailey , Haddad Tyler , Krane Jeffrey F. , Lindeman Neal I. , Shapiro Geoffrey I. , Haddad Robert I. , Hammerman Peter S.
Published: April 2023

Presence of MCL1 Amplification is Associated with Progression-Free Survival Across the Oncopanel Cohort (n=109).
Supplementary Figure 2 from Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
Authors: Chau Nicole G. , Li Yvonne Y. , Jo Vickie Y. , Rabinowits Guilherme , Lorch Jochen H. , Tishler Roy B. , Margalit Danielle N. , Schoenfeld Jonathan D. , Annino Don J. , Goguen Laura A. , Thomas Tom , Becker Hailey , Haddad Tyler , Krane Jeffrey F. , Lindeman Neal I. , Shapiro Geoffrey I. , Haddad Robert I. , Hammerman Peter S.
Published: April 2023

Presence of IKZF1 Amplification is Associated with Progression-Free Survival Across the Oncopanel Cohort (n=109).
Supplementary Table S8 from Identification and Functional Validation of Reciprocal microRNA–mRNA Pairings in African American Prostate Cancer Disparities
Authors: Wang Bi-Dar , Ceniccola Kristin , Yang Qi , Andrawis Ramez , Patel Vyomesh , Ji Youngmi , Rhim Johng , Olender Jacqueline , Popratiloff Anastas , Latham Patricia , Lai Yinglei , Patierno Steven R. , Lee Norman H.
Published: April 2023

Supplementary Table S8. Significant pathways identified by GSEA in A) AA PCa vs. EA PCa, B) AA PCa vs AA NP, and C) EA PCa vs EA NP
Supplementary Tables and Figure from A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
Authors: Appleman Leonard J. , Balasubramaniam Sanjeeve , Parise Robert A. , Bryla Christine , Redon Christophe E. , Nakamura Asako J. , Bonner William M. , Wright John J. , Piekarz Richard , Kohler David R. , Jiang Yixing , Belani Chandra P. , Eiseman Julie , Chu Edward , Beumer Jan H. , Bates Susan E.
Published: April 2023

Supplementary Tables 1-3. Supplemental Table 1. Plasma pharmacokinetics of DMS612 metabolites. Supplemental Table 2. Pharmacodynamic assessment of !-H2AX detection in PBMCs. Mean values for !-H2AX foci per cell with DMS612 doses of 1.5, 3, 5, 7, 9 and 12 mg/m2 at the indicated time in hours (h). Supplemental Table 3. Pharmacodynamic assessment of !-H2AX detection in hair follicles. Mean values for cell with more than 4 !-H2AX foci per cell in plucked scalp hairs with DMS612 doses of 1.5, 3 and 9 mg/m2 at the indicated time in hours (h). Supplemental Figure 1. Pharmacokinetics of DMS612 Metabolites.
Supplementary Table S4 from Identification and Functional Validation of Reciprocal microRNA–mRNA Pairings in African American Prostate Cancer Disparities
Authors: Wang Bi-Dar , Ceniccola Kristin , Yang Qi , Andrawis Ramez , Patel Vyomesh , Ji Youngmi , Rhim Johng , Olender Jacqueline , Popratiloff Anastas , Latham Patricia , Lai Yinglei , Patierno Steven R. , Lee Norman H.
Published: April 2023

Supplementary Table S4. Population-associated mRNAs. A) AA-enriched and depleted mRNAs, B) AA-specific mRNA, and C) EA-specific mRNAs
Supplementary Figure Legends and Figures S1 and S2 from Identification and Functional Validation of Reciprocal microRNA–mRNA Pairings in African American Prostate Cancer Disparities
Authors: Wang Bi-Dar , Ceniccola Kristin , Yang Qi , Andrawis Ramez , Patel Vyomesh , Ji Youngmi , Rhim Johng , Olender Jacqueline , Popratiloff Anastas , Latham Patricia , Lai Yinglei , Patierno Steven R. , Lee Norman H.
Published: April 2023

Supplementary Figure Legends and Figures for Figure S1: IHC assays of MCL-1, STAT1 and FOXO3A on FFPE samples from AAs and EAs; and Figure S2: Functional evaluation of miR-145/ITPR2 and miR-34a/PPP2R2A pairs in AA PCa cell lines.
Supplementary Methods, Table S1, Figures S1-7 from Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer
Authors: Blume-Jensen Peter , Berman David M. , Rimm David L. , Shipitsin Michail , Putzi Mathew , Nifong Thomas P. , Small Clayton , Choudhury Sibgat , Capela Teresa , Coupal Louis , Ernst Christina , Hurley Aeron , Kaprelyants Alex , Chang Hua , Giladi Eldar , Nardone Julie , Dunyak James , Loda Massimo , Klein Eric A. , Magi-Galluzzi Cristina , Latour Mathieu , Epstein Jonathan I. , Kantoff Philip , Saad Fred
Published: April 2023

Supplementary Methods, Table S1, Figures S1-7. Methods for quantitative multiplex proteomics imaging (QMPI) Clinical studies: Statistical plan Table S1. Clinical Validation Study. Comparison of Predictive Value of the 8-Biomarker Assay for Favorable Pathology with D'Amico Risk Categories. Figure S1. Outline of all four quantitative multiplex immunofluorescence triplex assay formats Figure S2. Clinical validation study, full cohort (N=276): performance for "GS 6" pathology (surgical Gleason =3+3 and localized {less than or equal to}T3a). A) Sensitivity (P[risk score> threshold| "non-GS 6" pathology]) of the assay, as a function of medical decision level. Figure S3. Clinical validation study, full cohort (N=274): performance for prediction of favorable pathology (surgical Gleason {less than or equal to}3+4 and organ-confined {less than or equal to}T2). Figure S4. Clinical validation study, Subset of validation cohort that contained sufficient annotation for National Comprehensive Cancer Network (NCCN) and D'Amico categorization (N=256) Figure S5. Clinical validation study: performance for prediction of favorable pathology. Figure S6. Net Reclassification Index analysis illustrates how biomarker assay categories of favorable (risk score {less than or equal to}0·33) and non-favorable (risk score >0·8) may supplement NCCN Figure S7. Decision Curve Analysis provides another method for characterizing performance of different risk systems and at different cut points.
Supplementary Figures S1-4 and Tables S1-6 from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Authors: Asundi Jyoti , Crocker Lisa , Tremayne Jarrod , Chang Peter , Sakanaka Chie , Tanguay Josh , Spencer Susan , Chalasani Sreedevi , Luis Elizabeth , Gascoigne Karen , Desai Rupal , Raja Rajiv , Friedman Brad A. , Haverty Peter M. , Polakis Paul , Firestein Ron
Published: April 2023

Supplementary Figures S1-4 and Tables S1-6. Supplementary Figure S1. LY6E is overexpressed in a subset of breast cancers Supplementary Figure S2. LY6E transcript expression in normal human tissues is shown. Supplementary Figure S3. Endocytosis of anti-LY6E antibody 9B12 Supplementary Figure S4. LY6E ADC activity in MAXF-1162, a HER2+/ T-DM1 resistant breast cancer model. Supplementary Table S1. Table lists the relative LY6E protein expression detected by IHC Supplementary Table S2. Anti-LY6E antibody 9B12 affinity to human and cynomolgus monkey LY6E. Supplementary Table S3. The correlation of LY6E copy number to anti-LY6E ADC killing in a panel of ovarian cancer cell lines is shown Supplementary Table S4. LY6E and GAPDH specific primer and probe sets used for transcript analysis and LY6E specific siRNAs are listed. Supplementary Table S5. Detailed percent tumor growth inhibition data for xenograft efficacy studies presented in Fig. 6 and in Supplementary Fig. S4B. Supplementary Table S6. Statistical analyses of differences between tumor growth in test groups versus vehicle control group
Supplemental Methods and Figure Legends from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Authors: Asundi Jyoti , Crocker Lisa , Tremayne Jarrod , Chang Peter , Sakanaka Chie , Tanguay Josh , Spencer Susan , Chalasani Sreedevi , Luis Elizabeth , Gascoigne Karen , Desai Rupal , Raja Rajiv , Friedman Brad A. , Haverty Peter M. , Polakis Paul , Firestein Ron
Published: April 2023

Supplemental Methods and Figure Legends. Supplementary methods to the article as well as figure legends to the supplementary figures and supplementary tables are provided.
Supplemental Data 12 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Authors: Lambertz Irina , Kumps Candy , Claeys Shana , Lindner Sven , Beckers Anneleen , Janssens Els , Carter Daniel R. , Cazes Alex , Cheung Belamy B. , De Mariano Marilena , De Bondt An , De Brouwer Sara , Delattre Olivier , Gibbons Jay , Janoueix-Lerosey Isabelle , Laureys Geneviève , Liang Chris , Marchall Glenn M. , Porcu Michael , Takita Junko , Trujillo David Camacho , Van Den Wyngaert Ilse , Van Roy Nadine , Van Goethem Alan , Van Maerken Tom , Zabrocki Piotr , Cools Jan , Schulte Johannes H. , Vialard Jorge , Speleman Frank , De Preter Katleen
Published: April 2023

Supplemental data 12: Results of Connectivity map analysis performed on ALK signature genes.
Supplemental Table S2 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Authors: Tobin Nicholas P. , Wennmalm Kristian , Lindström Linda S. , Foukakis Theodoros , He Liqun , Genové Guillem , Östman Arne , Landberg Göran , Betsholtz Christer , Bergh Jonas
Published: April 2023

Univariable hazard ratios for distant metastasis-free survival per 25 increment increase in MV score in patient subsets of four independent datasets
Supplemental Figure S2. Concordance index of the PAM50 and GGI signatures in combination with the MV score in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Authors: Tobin Nicholas P. , Wennmalm Kristian , Lindström Linda S. , Foukakis Theodoros , He Liqun , Genové Guillem , Östman Arne , Landberg Göran , Betsholtz Christer , Bergh Jonas
Published: April 2023

The concordance index of the PAM50 and GGI signatures alone or in combination with the MV score in four independent datasets